Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.55 |
| ▸ | CPB1 | P15086 | 1/20 | 0.55 |
| ▸ | GGT1 | P19440 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839540 | 1.00 | CPB2 (0.55) | CPB2CPB1GGT1ALDH1A1CYP1A2 | |
| SCHEMBL2776305 | 0.92 | CPB2 (0.49) | CPB2CPB1GGT1ALDH1A1CYP1A2 | |
| SCHEMBL1079150 | 0.89 | CPB2 (0.47) | CPB2CPB1SLC15A2 | |
| SCHEMBL7738753 | 0.86 | CPB2 (0.49) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7738755 | 0.86 | CPB2 (0.49) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL29071837 | 0.84 | CPB2 (0.50) | CPB2CPB1GGT1ALDH1A1CYP1A2 | |
| SCHEMBL4247225 | 0.84 | CPB2 (0.40) | CPB2CPB1 | |
| SCHEMBL4247228 | 0.84 | CPB2 (0.40) | CPB2CPB1 | |
| SCHEMBL7074055 | 0.84 | CPB2 (0.40) | CPB2CPB1GGT1ALDH1A1CYP1A2 | |
| SCHEMBL10777853 | 0.84 | CPB2 (0.40) | CPB2CPB1GGT1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | CPB2 234/4885CPB1 168/4885GGT1 1034/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | CPB2 167/4885CPB1 181/4885GGT1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.